CMS NEWS
FOR IMMEDIATE RELEASE
January 18, 2019
Contact: CMS Media
Relations
(202) 690-6145 | CMS Media Inquiries
CMS Announces New Model to Lower Drug Prices in Medicare Part D
and Transformative Updates to Existing Model for Medicare Advantage
Models to provide seniors with more benefits while strengthening competition among plans
Today, CMS’s Center for
Medicare and Medicaid Innovation (“Innovation Center”), which tests
innovative payment and service delivery models to lower costs and improve the
quality of care, announced a new payment model and transformative updates to
an existing model. The models are designed to enable Medicare Advantage
and Part D plans, which are private plans that provide Medicare beneficiaries
with medical and prescription drug coverage, to better serve patients and
help them achieve good health.
“Expanding choices for
patients, aligning incentives, and providing new flexibility for insurers in
Medicare Advantage and Medicare Part D will deliver better value from these
programs,” said HHS Secretary Alex Azar. “The models being announced
today create new incentives for plans, patients, and providers to choose
drugs with lower list prices, and new ways to meet the unique healthcare needs
of specific populations, prevent disease, and expand the use of
telehealth. Today’s announcement draws on successes we have already
seen in Medicare and advances our priority of using HHS programs to build a
value-driven healthcare system.”
The model for Medicare
Advantage plans is an update to the Medicare Advantage Value-Based Insurance
Design or “VBID” model that CMS first launched in 2017. The model for
Part D plans is called the Part D Payment Modernization model. These
are both voluntary models to advance innovation – meaning certain Medicare
Advantage and Part D plans can choose to participate, and patients can choose
to enroll in participating plans. The models will be closely monitored,
and if they clear certain thresholds for impact on quality, costs, and access
to benefits, the models can be expanded in scope.
“The American healthcare
system is very different today than it was thirteen years ago when the
Medicare Advantage and Part D programs were launched in their current forms,
but due to the slow pace of change in government, these programs have not
been fully updated to reflect today’s realities,” said CMS Administrator
Seema Verma. “Today’s announcements are prime examples of how CMMI can
test policies to modernize CMS programs and ensure that our seniors can
access the latest benefits. These two models ignite greater competition
among plans, creating pressure to improve quality and lower costs in order to
attract beneficiaries.”
The President’s Blueprint
to Lower Drug Prices and Reduce Out-of-Pocket Costs called on HHS to increase
competition, improve negotiation, create incentives for lower list prices,
and reduce out-of-pocket costs. Through the Part D Payment
Modernization model announced today, CMS is executing on the Blueprint.
This model advances President Trump’s commitment to lower prescription drug
prices, with Medicare beneficiaries, Part D plans, and CMS all benefiting
from a more aligned system.
The Part D Payment
Modernization model announced today advances President Trump’s commitment to
lower prescription drug prices. Currently in Part D, once a patient’s
prescription drug spending is high enough for the patient to enter the final
phase of the benefit, known as the “catastrophic phase,” Medicare is
responsible for 80 percent of drug costs. This introduces perverse
incentives and leaves plans with little reason to negotiate lower costs for
the highest-spending patients.
In fact, over the past 10
years (2008-2017), federal spending in the Part D catastrophic phase has
nearly quadrupled from $9.4 billion to $37.4 billion, reflecting an average
increase of 17 percent per year. In 2016, 3.2 million beneficiaries
reached the Part D catastrophic phase, and the beneficiaries in catastrophic
who did not qualify for the low-income subsidy faced average annual
out-of-pocket drug costs of over $3,000.
This issue of plans having
limited responsibility in the catastrophic phase, and the related lack of
incentives plans have to focus on high list prices, was raised in the
President’s FY 2019 budget, and it has been highlighted by MedPAC and by
multiple other stakeholders in response to CMS RFIs. Under the new
model, which takes effect for the 2020 plan year, participating plans will
take on greater risk for spending in the catastrophic phase of Part D,
creating new incentives for plans, patients, and providers to choose drugs
with lower list prices. Based on plan year performance, CMS will
calculate a spending target for what governmental spending would have been
without plans taking on this additional risk. Participating Part D
plans will share in savings if they stay below the target but will be
accountable for losses if they exceed the target. For the first time,
the model also introduces a Part D rewards and incentives program to align
this model with the changes to VBID, and to provide Part D plans with
additional tools to control drug costs and help enrollees in choosing drugs
with lower list prices.
The wide-ranging
enhancements to the VBID model announced today will test a new series of
service delivery approaches for Medicare Advantage plan beneficiaries for the
2020 plan year, including:
Beginning in the 2021 plan
year, the VBID model will also test allowing Medicare Advantage plans to
offer Medicare’s hospice benefit. This change is designed to increase
access to hospice services and facilitate better coordination between
patients’ hospice providers and their other clinicians.
Plans participating in the
VBID program will be offered along with traditional Medicare Advantage
plans. CMS will monitor whether plans that take up these more tailored
coverage options are able to reduce costs and increase quality.
Medicare Advantage plans
in all 50 states and territories may apply for the VBID model for 2020,
thanks to a provision signed into law by President Trump in the Bipartisan
Budget Act of 2018. Additionally, the model is now available to more
Medicare Advantage plan types, including all Special Needs Plans and Regional
PPOs in all states and territories. The Part D Payment Modernization
and VBID models will run through 2024. Requests for Applications for
participating in the VBID model for 2020 and the Part D Payment Modernization
model for 2020 will be made available by CMS the week of January 21,
2019. Medicare beneficiaries will be able to select plans participating
in these models for the 2020 plan year.
Today, CMS is also issuing
an evaluation report for the first year of the VBID model. Plans in
only 7 states could participate in the model for the first year (2017).
The report shows that participating plans began to leverage the new tools
that were introduced right away, with 45 plans participating and offering
more benefits to enrollees. Most 2017 Medicare Advantage data are not
yet complete for a full impact analysis, but the agency is continuing to
assess the model. Today’s update of VBID was informed by experience
during the early years of the model.
For fact sheets on today’s
announcements, please visit https://cms.gov/newsroom/fact-sheets/value-based-insurance-design-model-vbid-fact-sheet-cy-2020
and https://cms.gov/newsroom/fact-sheets/part-d-payment-modernization-model-fact-sheet.
###
Get CMS news at cms.gov/newsroom, sign up for CMS news via email and follow CMS on Twitter CMS
Administrator @SeemaCMS, @CMSgov, and @CMSgovPress.
|
|
To be a Medicare Agent's source of information on topics affecting the agent and their business, and most importantly, their clientele, is the intention of this site. Sourced from various means rooted in the health insurance industry - insurance carriers, governmental agencies, and industry news agencies, this is aimed as a resource of varying viewpoints to spark critical thought and discussion. We welcome your contributions.
Friday, January 18, 2019
CMS Announces New Model to Lower Drug Prices in Medicare Part D and Transformative Updates to Existing Model for Medicare Advantage
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment